Covalent targeting of acquired cysteines in cancer.

Abstract excerpt

The thiolate side chain of cysteine has a unique functionality that drug hunters and chemical biologists have begun to exploit. For example, targeting cysteine residues in the ATP-binding pockets of kinases with thiol-reactive molecules has afforded increased selectivity and potency to drugs like imbrutinib, which inhibits the oncogene BTK, and CO-1686 and AZD9291 that target oncogenic mutant EGFR. Recently,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cysteine
• Share to BTK gene
• Share to KRAS gene